From July 1, 2023 to September 30, 2023, the company has repurchased 80,000 shares, representing 0.67% for CAD 0.6 million. With this, the company has completed the repurchase of 306,700 shares, representing 2.55% for CAD 2.27 million under the buyback announced on December 13, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 CAD | +3.16% | -1.05% | -7.81% |
22/04 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
01/04 | BioSyent To Present At LD Micro New York Investor Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.81% | 7.03Cr | |
+33.21% | 71TCr | |
+30.77% | 60TCr | |
-2.05% | 37TCr | |
+20.00% | 33TCr | |
+5.26% | 29TCr | |
+14.77% | 24TCr | |
+9.13% | 21TCr | |
-3.97% | 20TCr | |
+9.34% | 17TCr |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.